Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pharmapnea
Gothenburg, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
Pharmapnea is a clinical-stage biotechnology company focused on developing pharmacological treatments for obstructive sleep apnea (OSA). The company's lead candidate, PHAR-001, is a combination therapy designed to address the underlying physiological causes of airway collapse during sleep. By targeting specific ion channels and metabolic pathways, Pharmapnea aims to provide a non-invasive alternative to continuous positive airway pressure (CPAP) machines. The company is currently advancing its pipeline through Phase 2 clinical trials to demonstrate efficacy in reducing the apnea-hypopnea index (AHI) and improving patient sleep quality.
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Pharmapnea.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmapnea.